715-42-4 Usage
Uses
Used in Pharmaceutical Industry:
2,4-DICHLORO-5-NITRO-6-(TRIFLUOROMETHYL)PYRIMIDINE is used as a chemical intermediate for the preparation of Spiroheterocycl-dihydropteridinones. These compounds act as modulators of γ-secretase, an enzyme involved in the processing of amyloid precursor protein (APP) in the brain. By modulating γ-secretase activity, Spiroheterocycl-dihydropteridinones have the potential to treat Alzheimer's disease, a neurodegenerative disorder characterized by the accumulation of amyloid-beta plaques and neurofibrillary tangles in the brain.
In the development of Alzheimer's therapeutics, 2,4-DICHLORO-5-NITRO-6-(TRIFLUOROMETHYL)PYRIMIDINE plays a crucial role in the synthesis of compounds that can selectively modulate γ-secretase, thereby reducing the production of amyloid-beta peptides and potentially slowing down the progression of the disease. This makes it a valuable component in the ongoing research and development of novel treatments for Alzheimer's disease.
Check Digit Verification of cas no
The CAS Registry Mumber 715-42-4 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 7,1 and 5 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 715-42:
(5*7)+(4*1)+(3*5)+(2*4)+(1*2)=64
64 % 10 = 4
So 715-42-4 is a valid CAS Registry Number.
715-42-4Relevant academic research and scientific papers
DIHYDROPTERIDINONES II
-
Page/Page column 81, (2014/09/03)
The present invention relates to spiroheterocycl-dihydropyhmidines, their use as modulators of γ-secretase and to pharmaceutical compositions containing said compounds. In particular, the present invention relates to compounds which interfere with γ-secretase and/or its substrate and therefore modulate the formation of Αβ peptides.
DIHYDROPTERIDINONES II
-
Paragraph 0413, (2013/09/12)
The present invention relates to spiroheterocycl-dihydropyrimidines, their use as modulators of γ-secretase and to pharmaceutical compositions containing said compounds. In particular, the present invention relates to compounds which interfere with γ-secretase and/or its substrate and therefore modulate the formation of Aβ peptides.
